Edward Bradley, MD, gives an overview of the mechanism of action and development of moxetumomab pasudotox, a monoclonal antibody directed at CD22.
Edward Bradley, MD, Senior Vice President, Head, Innovative Medicines unit (iMED), MedImmune (the global biologics research and development arm of AstraZeneca), gives an overview of the mechanism of action and development of moxetumomab pasudotox.
Moxetumomab pasudotox is a monoclonal antibody made up of an antibody directed at CD22 and Pseudomonas exotoxin. The agent binds to CD22 on the surface of the tumor cell and is incorporated into the cell before the Pseudomonas exotoxin metabolizes, is released, and kills the cell.
In a phase I trial, patients with hairy cell leukemia who had failed previous therapy saw over 90% response rate, with over half being complete responses. Bradley said that the durability of the responses was most striking and that moxetumomab pasudotox was well-tolerated.